The Role of FAM19A4 & Hsa-mir-124 Methylation in Predicting Prognosis of

Status Recruiting

Clinical Trial Summary

High-risk precancerous cervical lesions are divided into stage 2 and 3 cervical intraepithelial neoplasia (CIN 2 and 3). CIN 3 represents a direct pre-stage of invasive cancer, has a high rate of progression and a high degree of agreement with the final histological diagnosis. In CIN 2 lesions, the rate of agreement with the final histological diagnosis is lower and the rate of spontaneous regression is higher. Due to the higher rate of regression and possible complications after excisional treatment, conservative active monitoring can be considered in selected young CIN 2 patients. A recent meta-analysis reported a high rate of spontaneous clinical regression of CIN 2, particularly in women under 30 years old. There are currently no prospectively validated prognostic biomarkers to determine which CIN 2 will progress to higher grade and which will regress to lower grade of change. Recent research has studied HPV methylation and microbiome analysis as biomarkers. A number of studies have shown that host cell DNA methylation levels in cervical scrapes increase with underlying cervical disease severity and are highest in cervical cancer. DNA methylation involves the covalent binding of a methyl group to the 5´ position of a cytosine molecule in CpG dinucleotides. Besides global hypomethylation, the overall loss of methylation during carcinogenesis, resulting in chromosomal instability, and the silencing of tumour suppressor genes by local hypermethylation of CpG-rich promoter regions contribute to cancer development. Gene promoter methylation can be easily accessed by sensitive, quantitative methylation-specific PCR providing an objective test outcome. The aim of this study was to determine the effect of the methylation rate of two suppressor genes- FAM19A4 and hsa-mir-124 on the rate of CIN 2 regression, persistence or progression in women younger than 36 years (≤35 years old).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05624827
Study type	Interventional
Source	University Medical Centre Maribor
Contact	Milena Miklus, MD
Phone	+386 2 321 2178
Email	milena.rmus4@gmail.com
Status	Recruiting
Phase	N/A
Start date	September 1, 2021
Completion date	May 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03642574` - Preimplantation DNA Methylation Test (PIMT) in ART	N/A
Completed	`NCT03787849` - Epigenetics in PostOperative Pediatric Emergence Delirium	N/A
Recruiting	`NCT05442125` - First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization	N/A
Completed	`NCT05085847` - Effects of Mindfulness-based Intervention on Epigenetic Mechanisms, Cognition Function, Stress Response, and Well-being	N/A
Recruiting	`NCT04651946` - Cell-free DNA Methylation for Epithelial Ovarian Cancer	Phase 2
Recruiting	`NCT04646954` - DNA Methylation Testing for the Screening of Uterine Cervical Lesion	Phase 3
Recruiting	`NCT03961191` - DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
Not yet recruiting	`NCT05779904` - Methylation, mIcrobiome, NUtritional sTatus, and dEvelopment of Stunted Children
Recruiting	`NCT05791149` - Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity	N/A
Recruiting	`NCT05801276` - ctDNA Methylation for Detecting Ovarian Cancer
Recruiting	`NCT05801263` - ctDNA Methylation for Epithelial Ovarian Cancer
Recruiting	`NCT05290415` - Host DNA Methylation for Endometrial Cancer Screening
Recruiting	`NCT05290428` - DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening
Recruiting	`NCT05290922` - DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening
Recruiting	`NCT03960879` - DNA Methylation for Screening Uterine Cervical Lesions
Recruiting	`NCT05737953` - Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
Recruiting	`NCT06140992` - PaCIFiC-CUP Classifies Cancer of Unknown Primary
Completed	`NCT02032628` - DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise	N/A
Completed	`NCT04568512` - DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture	N/A
Completed	`NCT03227003` - DNA Methylation and 1-C Metabolism Nutrient Intake	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms